The Weekly Recap 7/24/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni receive new funding, appoint new executives, receive regulatory approvals, and much more on the road to LSI Europe ‘26 in Barcelona (September 28 - October 1).

ABILITY Neurotech

Completed the first-in-human procedure for its BCI technology. The system is designed to capture high-resolution brain signals and transmit large volumes of lossless neural data at significantly higher bandwidth than Bluetooth-based systems through a minimally invasive, long-term implant.

AiM Medical Robotics

Appointed Andrew Aberdale as President and CFO. Aberdale brings more than thirty years of deep operational and financial leadership, with a highly successful track record of commercializing early-stage ventures to successful exits, executing high-value corporate exits, and driving rapid organizational growth.

Aptyx

Appointed David Price as CEO after serving as the company’s Chief Financial Officer since 2025. Price brings financial, operational, and commercial leadership experience and has helped strengthen execution and position the company for its next phase of growth.

BMI OrganBank

Received an undisclosed investment from Cowtown Angels. The company is developing a room-temperature organ preservation platform that maintains kidneys in a metabolically active state, continuously delivering oxygen and nutrients without requiring donated blood.

BrightHeart

Welcomed Bastien Maulin as its new Head of Marketing. Maulin brings experience in brand building, sales enablement, AI, and medtech, alongside a strong foundation in storytelling developed in the entertainment industry. 

Corbotics

Received ISO 13485:2016 certification from BSI, confirming its quality management system meets international medical device standards. The certification covers the design, development, and manufacturing of the company’s cardiac echo robot and supports compliance with global regulatory requirements.

Medyria

Secured a CHF 3.5M investment round. The capital will provide the financial runway to propel its flagship PyCath project forward into the U.S. market and advance its mission to revolutionize minimally invasive medical procedures.

Moon Surgical & KARL STORZ

Announced a strategic commercial collaboration that pairs Moon Surgical's Maestro^® platform with KARL STORZ 3D visualization and instrumentation to give surgical teams a more complete and more capable laparoscopic environment. The collaboration is designed to expand care teams' access to innovative surgical technology and to advance Scalable Surgery, Moon Surgical's vision for making minimally invasive surgery more predictable and more widely accessible.

NovoMed PARTNERS

Officially launched as an operator-led healthcare platform built to create, scale, and accelerate transformational medical technology companies. The firm’s mission is to partner with extraordinary leaders and innovators to turn promising ideas into enduring companies and bring meaningful innovation to more patients around the world.

PainChek

Welcomed LSI Alumni Karen Holzberger as CEO. Holzberger has 26 years of healthcare leadership, delivering revenue generation and strategic growth initiatives in U.S. early-stage and large international medtech companies.

Prevencio

Granted a new Proprietary Laboratory Analyses (PLA) Current Procedural Terminology (CPT^®) billing code by the AMA for the company's HART PAD blood test for peripheral artery disease. The award of a dedicated PLA code represents the company’s fourth AMA-issued proprietary CPT billing code, further strengthening its reimbursement infrastructure and commercial leadership in AI-driven blood diagnostics.

Rob Surgical

Received CE mark for the use of its ROB^® surgical robot and associated instruments in urological surgical procedures. The platform is designed for minimally invasive surgery and integrates four robotic arms on a single cart with an open architecture that supports seamless integration into existing operating rooms and surgical workflows.

SpinaFX

Received MDR CE Mark certification for its Triojection^® System. The Triojection system is an image‑guided, minimally invasive device designed to deliver a controlled ozone‑oxygen gas mixture for several medically valid procedures, including intervertebral disc injections for patients suffering from persistent pain due to contained lumbar disc herniation who have failed conservative therapies.

Thrombolex

Welcomed LSI Alumni Michael Tutera as CEO. Tutera brings a proven track record of driving commercial excellence, aligning clinical, economic, and reimbursement strategies, and building high-performing teams. 

Twinsight

Closed a €1.6M seed round to accelerate U.S. commercialization. The raise combines equity financing with non-dilutive bank loans, secured with the support of Bpifrance, Caisse d'Epargne, and Crédit Agricole Sud Rhône Alpes.

TYBR Health

Closed a $30M Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The company will use the funds to expand commercial access to its FDA-cleared B3 GEL^® System, broaden its product indications, and run clinical studies evaluating tissue protection during orthopedic surgery.

Xenter

Closed a $58.3M Series B financing round with participation from existing shareholders, prominent family offices, and healthcare investors. The proceeds will support commercial launch, continued development of its proprietary technologies, manufacturing expansion, clinical and regulatory initiatives, and the acceleration of the company’s integrated TechMed platform.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.